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Risk Factors for cocaine-induced psychosis in cocaine dependent patients 
 
Abstract 
Cocaine consumption can induce transient psychotic symptoms, expressed as paranoia 
or hallucinations. Cocaine induced psychosis (CIP) is common but not developed in all 
cases. This is the first European study on the relationship between CIP, consumption 
pattern variables and personality disorders. We evaluated 173 cocaine-dependent 
patients over 18 years; mostly males, whose average age was 33.6 years (SD = 7.8). 
Patients attending an outpatient addictions department were enrolled in the study and 
subsequently systematically evaluated using, SCID I and SCID II interviews for 
comorbid disorders, a clinical interview for psychotic symptoms and EuropASI for 
severity of addiction. A high proportion of cocaine dependent patients reported 
psychotic symptoms under the influence of cocaine (53.8%), the most frequently 
reported being paranoid beliefs and suspiciousness (43.9%). A logistic regression 
analysis was performed, finding that a model consisting of amount of cocaine 
consumption, presence of an antisocial personality disorder and cannabis dependence 
history had 66.2% sensitivity 75.8% specificity predicting the presence of CIP. In our 
conclusions we discuss the relevance of evaluating CIP in all cocaine dependent-
patients, and particularly in those fulfilling the clinical profile derived from our results. 
These findings could be useful for a clinical approach to the risks of psychotic states in 
cocaine-dependent patients. 
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Cocaine consumption and demands for treatment have increased in Europe in recent 
years. On average, in Europe 14 million Europeans have used it at least once in their 
life, (4.1 % of adults aged 15–64 years) and 4 million Europeans have used the drug in 
the last year (1.3 %), being Spain the leading European country in the consumption of 
cocaine (1). The US National Comorbidity Survey found that 3.8% of the general 
population has a substance use disorder, and 65% of drug dependent individuals 
develop at least one mental disorder throughout their lifetime (2, 3). Chronic 
consumption of cocaine can induce transient psychotic symptoms, expressed as 
paranoia or hallucinations. The term cocaine induced psychosis (CIP) has been used to 
describe this syndrome. These symptoms disappear typically with abstinence (4-8).  
Associating these symptoms with a DSM-IV diagnostic category is a complex process. 
CIP symptoms can appear with cocaine intoxication and they can also be present in 
psychotic disorders induced by cocaine. These diagnostic criteria are controversial and 
have been the subject of some criticism (9). Assessment of psychotic symptoms induced 
or exacerbated by cocaine in patients with chronic psychotic disorders such as 
schizophrenia or bipolar disorder is difficult because such patients often lack insight 
into their psychotic symptoms, whether or not they are cocaine-related. In contrast, 
cocaine users without chronic psychotic disorders, but who report CIP, almost always 
have retrospective insight into the distorted nature of their experiences during cocaine 
intoxication, even though they often lack such insight while intoxicated. 
Besides the risks associated with CIP symptoms, some studies have observed that drug 
dependent-individuals with cocaine induced paranoia are at higher risk of developing a 
psychotic disorder (4, 10). 
CIP prevalence is not exactly known; different studies have reported prevalences 
between 48% and 88% (11-13). The wide range of prevalences found are probably due 
to the variability and bias in the samples studied, the different study designs, 
instruments used for assessment, and administration routes used. 
As for the clinical factors that moderate the appearance of CIP, several factors have 
been found that increase the possibility of a CIP. Several researches agree with the idea 
that the amount of cocaine consumed both in laboratory and clinical studies (8, 14-17) 
and early-onset of cocaine use (6, 12, 14) are positively related to CIP. It has also been 
reported that the early-onset of cocaine dependence, or in vulnerable periods of brain 
development, may lead to increase the severity of CIP (14, 18). However, it has been 
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found that the number of years of cocaine use does not correlate with cocaine-induced 
psychosis (19). It has also been established that different routes of administration from 
the nasal airway like smoking (15) or intravenous use (17) may increase the risk of CIP. 
Comorbidity with other substance use disorders, such as cannabis use seems to play a 
mediating role for developing psychotic symptoms. Tang et al. observed a statistically 
significant difference in the frequency of CIP in cocaine dependent individuals based on 
cannabis dependence, but this difference did not remain statistically significant after 
adjusting for age and sex (7). Kalayasiri et al. recently found that adolescent–onset of 
cannabis use increases the risk of CIP in cocaine dependent individuals (12). 
CIP can be linked to hostile behaviours and antisocial personality disorder (ASPD). A 
pattern in which the stimulants generate hostility through psychotic symptoms has been 
suggested. This contributes to a perception of the environment as a hostile and 
threatening place, as well as through increasing impulsivity, thus CIP can trigger hostile 
behaviours (7, 20). 
Although the assessment of traits and personality disorders during heavy drug use is 
complex and there is debate about its stability (21, 22), comorbid Axis II disorders are 
especially prevalent in cocaine users. Several studies found prevalences of personality 
disorders ranging from 30 to 77% in inpatient or outpatient samples (10),  being 
antisocial and borderline personality disorders, the most prevalent (23). Kranzler et al. 
compared the frequency of CIP in patients with and without personality disorders but 
did not find significant differences (10). However, it is possible that antisocial 
personality traits are related with CIP. Recently, Tang identified that cocaine-dependent 
patients who experienced CIP tend to present a comorbid ASPD more frequently (7). 
Despite this, the relationship between personality disorders and psychotic symptoms 
induced by cocaine, are clearly not sufficiently analysed. 
This study examined the relationship between CIP and substance consumption variables 
and personality disorders, and attempted to identify risk factors for CIP. Although other 
studies have been published on this topic, this is the first to study both substance 
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2. Subjects and Methods 
2.1. Procedure 
We performed a cross-sectional, observational study. The participants were patients of 
the Psychiatric Department of the Vall d’Hebron Hospital (Barcelona, Spain). 
Specifically, they were cocaine-dependent patients treated in a Substance Use Disorders 
Unit, who began treatment between January 2006 and December 2008. This study is 
part of a more extensive research on the comorbidity in cocaine dependence.  
Inclusion criteria were: age over 18, cocaine dependence according to DSM-IV criteria, 
and signing the informed consent prior to participation. Exclusion criteria were: 
psychotic disorder or bipolar type I disorder, intoxication at baseline examination, 
severe somatic disease at baseline examination and low language proficiency. We 
excluded psychotic and bipolar patients in order to avoid the risk of not being able to 
distinguish primary and secondary symptomatology. However, its known that CIP can 
be measured in psychotic patients (24) The research was approved by the Ethics 
Committee of the Vall d’Hebron Hospital. Patients did not receive any financial 
compensation for taking part in this study. 
The evaluation process consisted of three interview sessions conducted by trained 
psychiatrists and psychologists. The psychiatrists performed the evaluation of substance 
use disorders, CIP and variables related with cocaine consumption; this interview 
corresponded to the first medical visit. Psychologists measured severity of substance 
use disorder and personality disorders in the second and third interviews. 
 
2.2. Participants 
From a total of 238 patients who contacted our unit, 173 finally took part in the study. 
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2.3. Data collection 
2.3.1. Cocaine Induced Psychosis (CIP). Trained psychiatrists systematically 
conducted a structured interview in which the conclusions from the sensoperceptive 
examinations were summarized. The patients were asked about the psychotic symptoms 
they had experienced under the influence of cocaine throughout their life. This 
examination included four questions about paranoid beliefs, auditory, visual and kinetic 
hallucinations. The questions were: 1) Have you ever heard, or thought you heard, 
something that wasn’t really there?  Did it happen while you were under the effects of 
cocaine?  2) Have you ever seen, or thought you saw something, that wasn’t actually 
there? Did it happen under the effects of cocaine? 3) Have you ever felt anything 
unusual on your body or on your skin?  Did it happen while you were under the effects 
of cocaine? 4) Have you believed that people were spying on you, or that someone was 
plotting against you, or trying to hurt you? Did it happen while you were under the 
effects of cocaine? Patients were considered CIP positive by the psychiatrist if they 
were marked positively in any of the above questions. 
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2.3.2. Severity of substance use disorder. The Spanish version of the European 
Addiction Severity Index (EuropASI) was used (25). This is a face-to-face structured 
interview which measures several domains: general medical information, alcohol and 
drug use, employment and support, family and social relationships, legal status and 
psychiatric status. The EuropASI is an adaptation of the fifth version of the Addiction 
Severity Index (26, 27). It is one of the most widely used assessment and diagnostic 
tools in Europe.  
2.3.3. Variables related with cocaine consumption. Amount of cocaine consumed per 
week, years of cocaine dependence and main cocaine route of administration at the 
beginning of the treatment were systematically registered. 
2.3.4. Substance Use Disorders. The Structured Clinical Interview for DSM IV Axis I 
disorders (SCID I) was used in order to identify substance use disorders (28). This tool 
is widely used and it has shown good psychometric properties (29). 
2.3.5. Personality Disorders. The Structured Clinical Interview for DSM IV Axis II 
Personality Disorders (SCID II) was used to evaluate this topic. This tool has shown 
adequate reliability and usefulness in providing fine discriminations between Axis II 
disorders (30). The Spanish translation has an overall kappa of 0.85(31). 
 
2.4. Data Analysis 
Data analysis was performed in three steps: descriptive, bivariate and multivariate 
analyses. The first step includes the description of all variables in terms of percentages, 
means and standard deviations. These variables were clustered in four groups: a) 
demographic variables, including gender, age, educational level and nationality, b) 
cocaine consumption pattern, including weekly amount of cocaine consumed, years of 
cocaine dependence and main cocaine route of administration c) lifetime substance use 
disorders, including cannabis, opioids, benzodiazepines, alcohol and tobacco 
dependence, and d) personality disorders (Antisocial Personality Disorder and 
Borderline Personality Disorder). The second step consisted in analyzing bivariate 
associations between each variable described above and CIP. The Kolmogorov-Smirnov 
test was used as a measure of normality. In this context, Mann-Whitney U and Chi-
square tests were performed.  In order to reduce the presence of some false positive 
effects, different Bonferroni corrections for multiple tests were performed. The 
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magnitude of each correction was a function of the number of variables in each of the 
four clusters of variables described above. Consequently, demographic variables were 
only considered significant with a P value less than .013 (.05/4). Variables included in 
the cocaine consumption pattern had a reference P value of .017 (amount of cocaine 
consumed per week, route of cocaine consumption, and years of cocaine dependence). 
In the case of the variables included in the substance dependences (cannabis, opioids, 
benzodiazepines, alcohol and tobacco) cluster the p value was .01 (.05/5) and in the case 
of personality disorders the P value was .025 (.05/2). Only the variables that exceeded 
the respective P values participated in the second analysis. In this step these variables 
were used in a multivariate logistic regression analysis as predictors, using backward 
conditional entry in order to perform an exploratory analysis including CIP as a 
dependent variable. In order to provide information on the adjustment of the resulting 
model, sensitivity (capacity to detect CIP subjects) and specificity (capacity to detect 
non CIP subjects) parameters were reported. Subsequently, in order to identify a 
symptomatic pattern, relations of psychotic symptoms with independent variables 
included in the model were analysed using bivariate statistics. All statistical hypotheses 
were two-tailed. SPSS, version 18.0 for Windows was used for all analyses. 
 
3. Results  
3.1. Descriptive information 
 
A shown in Table 1, most of the participants were young Spanish males and with 
primary school studies. The European Severity Index scores showed that employment 
status, family relationship and psychiatric status were the most affected domains. 
 
Table 1: Demographics, substance use disorders and EuropASI scores of the 
sample (n= 173) 
 
All subjects 
(n = 173) 
CIP (-) 
(n = 80) 
CIP (+) 






Males 80.3% 73.8% 86.02% 4.101  .043 
Mean age 33.6 32.68 34.63  -1.478 .139 
Completed primary 
school studies or less 
62.6% 61.1% 63.9% .147  .701 
Spanish Citizenship 91.1 % 93.7% 88.9% 1.189  .275 
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Mean EuropASI 
Medical status Mean .20 (SD= .27)      
Employment status Mean .50 (SD= .34 )      
Alcohol use Mean .25 (SD= .19)      
Substance use Mean .20 (SD= .22)      
Legal status Mean .13 (SD= .23)      
Family relationships Mean .36 (SD= .28)      
Psychiatric status Mean .35 (SD= .25)      
  
 
3.1.1. Cocaine Induced Psychosis symptoms 
Psychotic symptoms were found under the influence of cocaine in 53.8% of cocaine 
dependent-patients interviewed. The most frequently reported psychotic symptoms were 
paranoid beliefs and suspiciousness (43.9%). Auditory hallucinations were reported by 
30.9%, visual hallucinations by 26.1%, and kinaesthetic hallucinations by 10.3%. 
 
3.2. Bivariate analyses 
 
3.2.1. Consumption pattern and CIP 
Patients with CIP consumed larger amounts of cocaine per week in the month before 
they began treatment. They reported a mean of 12 grams per week (SD= 11.24) and 
patients without CIP reported 6 grams per week (SD= 9.61; difference between groups z 
= 3.44, p <.0001).  
With regards to cocaine route of administration, intranasal as the main administration 
route (73.8% in the whole sample) was significantly more frequent in patients without 
CIP (84% vs. 65.6%, 2= 7.278, P= .007). Among patients with CIP, 21.2% consumed 
intravenously and 12.8% smoked the cocaine. With respect to the years of cocaine 
dependence, we identified homogeneity between groups with and without CIP (9.5 and 
8.76 years respectively, z = 1.41, P=.156). From this group, amounts of cocaine 
consumed per week and the route of administration remained statistically significant 
after Bonferroni correction. 
 
3.2.2. Substance Use Disorders 
As can be seen in Table 2, we found that cocaine dependent patients with CIP tend to be 
cannabis and tobacco dependent throughout their lives more often than patients without 
CIP. From this group, only lifetime cannabis dependence remains statistically 
significant after Bonferroni correction. 
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Table 2: Personality Disorders and Substance use disorders in lifetime according 
to Cocaine Induced Psychosis  
 
 
CIP (-): Patients without Cocaine Induced Psychosis. 
CIP (+): Patients with Cocaine Induced Psychosis. 
 
3.2.3. Axis II 
As shown in Table 2, Borderline Personality Disorder (BPD) and ASPD were the most 
prevalent.  Only these showed a rate that allowed their statistical significance to be 
tested. When comparing patients with and without CIP, we found that both BPD and 
ASPD are associated with psychotic symptoms in consumption contexts. From this 
group, only antisocial personality disorder remains statistically significant after 
Bonferroni correction. 
 
3.3 Multivariate analysis   
A backward conditional logistic regression analysis was carried out in order to analyze 
all variables from the previous bivariate analysis that remained statistically significant 
after Bonferroni correction. These variables were: cocaine grams/week, antisocial 
personality disorder, lifetime cannabis dependence, and route of administration (we 
grouped this variable in intranasal versus the rest of routes due to the fact that 
 
All subjects 
(n = 173) 
CIP (-) 
(n = 80) 
CIP (+) 





Paranoid personality disorder 4.1% 0% 8.6%   
Schizoid personality disorder 1.6%  (3.1%) 0%   
Schizotypal  personality disorder 0% 0% 0%   
Antisocial personality disorder 16.9% 10.8% 26.2% 5.471 .019 
Borderline personality disorder 18.5% 10.8% 24.6% 4.279 .039 
Histrionic personality disorder 1.6% 1.5% 1.7%   
Narcissistic personality disorder 1.6% 0% 3.4%   
Avoidant personality disorder 2.4% 1.5% 3.4%   
Dependent personality disorder 2.4% 0% 4.6%   
Obsessive-compulsive personality disorder .8% 1.5% 0%   
Passive-aggressive behaviour 1.6% 0% 3.4%   
      
Cannabis dependence 35.2% 23.4% 45.5% 9.278 .002 
Opioid dependence 22.7% 21% 24.2% .002 .960 
Benzodiazepine dependence 11.8% 11.5% 12.1% .035 .851 
Alcohol dependence 22.8% 23% 22.7% .469 .493 
Tobacco dependence 84.4% 77.5% 89.9% 4.623 .032 
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absorption of smoked cocaine and iv injection is rapid in comparison with intranasal 
(32, 33). The two resulting models differed only in the route of administration as a 
predictor. Both models were statistically significant (First 2=21.501, p<.001, second 
2=19.122, p<.001) but no the step between them (2=2.379, p=.123), being the R 
squared higher for the first model (Cox=.156 vs. .140). This can happen due to the 
existence of a strong correlation among independent variables. Being all statistically 
associated, we decided to take all in account for the analysis due to its conceptual 
independence, but using conditional entry with the objective of discarding variables 
with low explicative capacity. 
 
Amount of cocaine and ASPD were significant in both models. Lifetime cannabis 
dependence had only a statistical tendency using a standard cut point of .05 (the 
standard criteria of non-inclusion in conditional models is .1). However, according to 
the literature, cannabis dependence could contribute to psychotic symptomatology (12, 
34, 35). Furthermore, we tested a model without cannabis dependence obtaining lower 
sensibility and specificity. Therefore, we maintained this variable in the model. Patients 
included in the CIP group with an ASPD were found to have a more symptomatology 
(paranoid beliefs and suspiciousness 2=5.917, p=.015; auditory hallucinations 
2=8.175, p=.017; visual hallucinations 2=12.908, p=.002 and kinaesthetic 
hallucinations 2=6.759, p=.034). In the same way, patients with history of cannabis 
dependence and CIP showed higher levels of symptomatology (paranoid beliefs and 
suspiciousness 2=9.167, p=.002; auditory hallucinations 2=5.961, p=.051; visual 
hallucinations 2=7.071, p=.029 and kinaesthetic hallucinations 2=6.942, p=.031). 
 
4. Discussion 
The present research examines the relationship of cocaine-induced psychosis with 
consumption patterns and personality disorders in cocaine dependent patients. The 
results shown that CIP is very common in cocaine-dependent patients who seek 
treatment, and particularly in patients who consume higher doses of cocaine, diagnosed 
with antisocial personality disorder and cannabis dependence throughout their lives.  
Although our objective was not to identify the prevalence of CIP, these results show a 
frequency of several psychotic symptoms reported by cocaine-dependent patients in a 
general hospital sample. Although these symptoms were communicated by more than 
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half of the patients seeking treatment, our study reports a relatively low rate of CIP 
probably because we failed to take in account behavioural symptoms. However, it has 
been hypothesized that the appearance of CIP in the first contacts with cocaine is 
associated with a lower risk of developing cocaine addiction (36). The most often 
reported psychotic symptoms were paranoid beliefs and suspiciousness. These results 
are consistent with results from previous investigations, which found frequencies 
between 48% and 88% (4, 6, 7, 11, 18).  
 
We also found that the amount of cocaine consumed at the beginning of treatment is a 
risk factor for CIP, consistently with data from retrospective reports and laboratory 
studies (8, 14, 16, 17). It has been reported that the substance use disorder severity is 
associated with the prevalence of psychotic symptoms, and that the prevalence of CIP is 
higher in dependent individuals than in abusers of cocaine (11), and in the most severely 
dependent patients (11, 12). One explanation for this finding could be related to the 
common pathways between cocaine mechanisms of action and psychosis neurobiology. 
Cocaine is believed to produce psychotic symptoms by increasing cortical and 
subcortical dopamine levels, and it is possible to identify an increased synaptic 
dopamine level both in the cocaine effects and in the positive psychotic symptoms (37), 
but this topic needs to be evaluated in future studies. This idea is consistent with 
Cubells et al. who analysed and identified the association between a haplotype at the 
DBH locus, with low plasma dopamine B-hydroxylase activity in patients with cocaine-
induced paranoia (38). 
 
The high frequency of CIP in cocaine-dependent patients gains importance because it 
involves potential risks for the patients and others. Lapworth et al. identified that both 
impulsivity and positive psychotic symptoms contribute independently to hostility in 
methamphetamine users (20). Nevertheless, their effects are amplified when they occur 
conjointly. They suggest that antisocial behaviours can be triggered by a dangerous 
perception of the environment, and the impulsivity produced by drug effects. If we 
assume that this situation can be similar in cocaine users, it is consistent to find more 
ASPD in patients with CIP, understanding that antisocial behaviours are influenced by 
an interaction of factors, such as drugs effect on the individual, social context and 
personality traits. ASPD and CIP have previously been proposed to be linked in 
cocaine-dependent patients by Tang et al. (7), but in their work did not remain 
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statistically associated after Bonferroni corrections. However, in our sample the 
relationship remained significantly associated. The association of ASPD with CIP 
suggests that there may be some common vulnerability factors that contribute to both 
cocaine-induced psychosis and aggressive behaviours (13). It can be based on a 
dysfunction in the dopaminergic receptors (6, 39-41). On the other hand anti-social 
individuals may be more likely to place themselves in dangerous or anxiety-provoking 
situations, leading to greater paranoia and visual and auditory hallucinations as well as 
be more likely to be cannabis dependent as our results show. However, these hypotheses 
should be studied more in depth. 
 
The high prevalence of cannabis use in primary cocaine-users is known to be around50-
70% (42, 43), or cocaine-dependent patients (35.4%) (13). A strong association between 
heavy cannabis use and the development of schizophrenia-spectrum psychoses has been 
described (44, 45). According to Kuepper et al. (46) cannabis is a risk factor for 
development of incident psychotic symptoms and might increase the risk for psychotic 
disorders by impacting on the persistence of symptoms. Nevertheless, previous works 
failed to associate the risk for CIP with lifetime cannabis use (12)or cannabis 
dependence (13). However we found that patients with CIP had significantly higher 
rates of cannabis dependence history than those without CIP. Kalayasiri et al. reported 
an earlier onset of cannabis use in patients with CIP than those without (12). Therefore, 
we conclude that high cannabis use could be related to CIP; understood as two 
situations, either an early-onset of use, or the development of cannabis dependence. It is 
possible that, there are common mechanisms within this association for the 
development of psychotic symptoms, such as neurobiological pathways that increase the 
risk of CIP. In the same study, the catechol-O-methyl-transferase (COMT) gene was 
studied but no interaction was found with early cannabis onset (12) . 
 
As limitations of the study, the self-reporting nature of the data must be considered. We 
evaluated cocaine-dependent patients who were seeking treatment and therefore, these 
results cannot be generalized to other cocaine-user populations. Cocaine amount used in 
consumption episodes with psychotic symptoms was not evaluated, for that reason the 
dose-effect relationship cannot be studied. We can only associate CIP with higher 
consumption at treatment onset. Another limitation is that symptom severity was not 
controlled, and our patients were not able to refer symptoms duration and intervention 
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needed. 
 
As strengths of the study, we believe that the multivariate analysis including 
consumption pattern variables and personality disorders is noteworthy. We offered a 
new model integrating previous knowledge: amount of cocaine consumption, presence 
of ASPD and cannabis lifetime dependence had a proper sensitivity and specificity to 
predict the presence of CIP. Furthermore, most previous studies have been performed 
with American population samples. This study has been carried out in Europe and could 
be considered relevant, due to the different consumption patterns present in this region, 
e.g. crack cocaine consumption is not still widespread in Europe (47). 
 
Finally, we consider that professionals who work with cocaine dependent-patients 
should incorporate these considerations into an integral approach. As CIP is very 
common in this population, clinicians should be especially attentive and explore it in 
patients who consume high quantities of cocaine, diagnosed of Antisocial Personality 
Disorder and/or cannabis dependence history. Identifying these types of symptoms can 
be useful to minimize the presence and risks during psychotic states. 
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